|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TSC22D2 |
Gene summary for TSC22D2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TSC22D2 | Gene ID | 9819 |
| Gene name | TSC22 domain family member 2 | |
| Gene Alias | TILZ4a | |
| Cytomap | 3q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DN36 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9819 | TSC22D2 | HCC1_Meng | Human | Liver | HCC | 5.49e-52 | -1.34e-01 | 0.0246 |
| 9819 | TSC22D2 | HCC2_Meng | Human | Liver | HCC | 3.86e-15 | -4.26e-02 | 0.0107 |
| 9819 | TSC22D2 | cirrhotic3 | Human | Liver | Cirrhotic | 8.46e-03 | -1.43e-01 | 0.0215 |
| 9819 | TSC22D2 | Pt13.b | Human | Liver | HCC | 2.23e-08 | -5.36e-02 | 0.0251 |
| 9819 | TSC22D2 | Pt13.c | Human | Liver | HCC | 3.41e-02 | -2.57e-01 | 0.0076 |
| 9819 | TSC22D2 | S027 | Human | Liver | HCC | 1.59e-02 | 6.66e-01 | 0.2446 |
| 9819 | TSC22D2 | S028 | Human | Liver | HCC | 2.05e-04 | 6.11e-01 | 0.2503 |
| 9819 | TSC22D2 | S029 | Human | Liver | HCC | 2.68e-03 | 5.42e-01 | 0.2581 |
| 9819 | TSC22D2 | TD9 | Human | Lung | IAC | 7.07e-03 | 6.11e-01 | 0.088 |
| 9819 | TSC22D2 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.55e-11 | 9.22e-01 | 0.3371 |
| 9819 | TSC22D2 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.56e-08 | 7.87e-01 | 0.343 |
| 9819 | TSC22D2 | RNA-P17T-P17T-6 | Human | Lung | IAC | 9.24e-09 | 7.24e-01 | 0.3385 |
| 9819 | TSC22D2 | RNA-P17T-P17T-8 | Human | Lung | IAC | 9.31e-11 | 7.69e-01 | 0.3329 |
| 9819 | TSC22D2 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.25e-06 | 4.10e-01 | -0.2116 |
| 9819 | TSC22D2 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 3.83e-07 | 4.91e-01 | -0.2119 |
| 9819 | TSC22D2 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.51e-03 | 1.79e-01 | -0.0166 |
| 9819 | TSC22D2 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 7.71e-08 | 2.48e-01 | -0.0132 |
| 9819 | TSC22D2 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 5.58e-06 | 1.75e-01 | -0.013 |
| 9819 | TSC22D2 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 7.32e-03 | 4.41e-01 | -0.0876 |
| 9819 | TSC22D2 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.29e-02 | 3.58e-01 | -0.0822 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006970 | Colorectum | SER | response to osmotic stress | 23/2897 | 84/18723 | 3.61e-03 | 3.03e-02 | 23 |
| GO:00069701 | Colorectum | FAP | response to osmotic stress | 25/2622 | 84/18723 | 1.43e-04 | 2.24e-03 | 25 |
| GO:00069704 | Endometrium | AEH | response to osmotic stress | 18/2100 | 84/18723 | 4.94e-03 | 3.12e-02 | 18 |
| GO:000697012 | Endometrium | EEC | response to osmotic stress | 19/2168 | 84/18723 | 2.98e-03 | 2.10e-02 | 19 |
| GO:00069707 | Esophagus | ESCC | response to osmotic stress | 57/8552 | 84/18723 | 3.26e-05 | 2.70e-04 | 57 |
| GO:00069703 | Liver | NAFLD | response to osmotic stress | 20/1882 | 84/18723 | 1.95e-04 | 3.41e-03 | 20 |
| GO:000697011 | Liver | Cirrhotic | response to osmotic stress | 34/4634 | 84/18723 | 1.06e-03 | 7.40e-03 | 34 |
| GO:00069702 | Liver | HCC | response to osmotic stress | 52/7958 | 84/18723 | 2.58e-04 | 1.92e-03 | 52 |
| GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
| GO:000697014 | Oral cavity | LP | response to osmotic stress | 32/4623 | 84/18723 | 4.36e-03 | 2.79e-02 | 32 |
| GO:00069705 | Prostate | BPH | response to osmotic stress | 27/3107 | 84/18723 | 3.35e-04 | 2.52e-03 | 27 |
| GO:000697013 | Prostate | Tumor | response to osmotic stress | 26/3246 | 84/18723 | 1.58e-03 | 9.63e-03 | 26 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TSC22D2 | SNV | Missense_Mutation | c.2204N>A | p.Ser735Tyr | p.S735Y | O75157 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TSC22D2 | SNV | Missense_Mutation | c.235N>C | p.Glu79Gln | p.E79Q | O75157 | protein_coding | tolerated(0.07) | probably_damaging(0.984) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
| TSC22D2 | SNV | Missense_Mutation | c.205N>C | p.Glu69Gln | p.E69Q | O75157 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| TSC22D2 | SNV | Missense_Mutation | novel | c.250N>A | p.Val84Ile | p.V84I | O75157 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
| TSC22D2 | SNV | Missense_Mutation | c.805N>G | p.Phe269Val | p.F269V | O75157 | protein_coding | tolerated(0.1) | benign(0.222) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TSC22D2 | SNV | Missense_Mutation | novel | c.293N>T | p.Ala98Val | p.A98V | O75157 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TSC22D2 | SNV | Missense_Mutation | c.2096N>T | p.Ser699Ile | p.S699I | O75157 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TSC22D2 | SNV | Missense_Mutation | c.2204N>A | p.Ser735Tyr | p.S735Y | O75157 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TSC22D2 | SNV | Missense_Mutation | novel | c.237G>T | p.Glu79Asp | p.E79D | O75157 | protein_coding | tolerated(0.06) | possibly_damaging(0.727) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| TSC22D2 | SNV | Missense_Mutation | novel | c.565G>A | p.Asp189Asn | p.D189N | O75157 | protein_coding | deleterious(0.01) | probably_damaging(0.909) | TCGA-AA-A02E-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |